Introduction
Interferons (IFNs) and retinoic acid (RA) exert dierent eects, such as inhibition of proliferation, induction of dierentiation and immunomodulation (Baron et al., 1991; De Luca, 1991) . The ecacy of IFNs and RA has been exploited in maintenance therapy for patients with various cell malignancies, including myeloid and lymphoid cell leukemias as well as various types of carcinoma (Baron et al., 1991; De Luca, 1991) . In IFN signaling, activation of the associated tyrosine kinases JAK1/JAK2 (for IFN-g) and JAK1/Tyk-2 (for IFN-a and IFN-b) leads to phosphorylation and homodimerization of the transcription factor STAT1a (p91) which is then translocated to the nucleus where it binds consensus sequences known as GAS motifs, to activate various gene promoters including interferon responsive factor-1 (IRF-1) gene (Igarashi et al., 1994; Watanabe and Arai, 1996; Silvennoinen et al., 1997; Hoey and Schindler, 1998) . RA modi®es gene expression by binding to speci®c nuclear RA receptors (De Luca, 1991) . However, recent studies indicate that RA can bypass IFN/IFN receptor interactions and induce the expression of some IFN-regulated genes including IRF-1, 2'5' oligosynthetase and PKR (Matikainen et al., 1996; Gianni et al., 1997; Pelicano et al., 1997) . RA induces the expression of IRF-1 gene expression in myeloid cell lines (Matikainen et al., 1996; Gianni et al., 1997; Pelicano et al., 1997) directly through its GAS motif (Pelicano et al., 1997) . Newly synthesized IRF-1 in turn can activate the expression of 2'5' oligosynthetase, IFN-a and PKR genes (Matikainen et al., 1996; Gianni et al., 1997; Pelicano et al., 1997) .
Transmembrane proteases have been implicated in the control of growth and dierentiation. One of these ectoenzymes, dipeptidylpeptidase IV (DPPIV) assigned to CD26, may be considered as a useful marker in some diseases. Overexpression of CD26 is observed in dierentiated thyroid (Tanaka et al., 1995) and liver (Stecca et al., 1997) carcinoma, on blood T cells from patients with autoimmune diseases (Ha¯er et al., 1985; Eguchi et al., 1989; Nakao et al., 1989) and in B cell chronic lymphocytic leukemia (B-CLL) (Bauvois et al., 1999) . In contrast, the loss of CD26 has been associated with T-CLL and ALL (Kondo et al., 1996) and melanoma progression (Wesley et al., 1999) .
The expression and regulation of CD26 seems to depend on the cell type and some physiological stimuli of CD26 expression have already been reported. IL-12 increased expression of CD26 on both CD4
+ and CD8 + activated T cells (Cordero et al., 1998) . On activated NK cells, CD26 is inducible by IL-2, IL-12 or IL-15, whereas interferon-g (IFN-g) has no eect (Yamabe et al., 1997) . In contrast, CD26 of renal epithelial cells is upregulated by IFN-g (Stefanovic et al., 1993) . IL-4 and Il-13 stimulate the expression of CD26 on human renal cell carcinoma and renal tubular epithelial cells (Riemann et al., 1995) . In the B lineage, CD26 is induced on human resting B lymphocytes during their in vitro activation with Staphylococcus aureus cowan I protein and IL-4 (BuÈ hling et al., 1994; Bauvois et al., 1999) . Consequently, little is known about the regulation of CD26 in B lineage cells and increased knowledge about the regulation of CD26 in B-CLL may be of clinical interest. The promoter of human CD26 gene contains several putative binding sites for transcription factors like Sp1, AP-1/2, ETF, HNF-1 and NF-kB (Abbott et al., 1994; BoÈ hm et al., 1995) . We found that CD26 promoter possesses one consensus GAS element (5'-TTCNNNGAA-3') present at 735 nucleotides from the mRNA start site. Computer analysis using the software developed by Quandt et al. (1995) con®rmed this sequence to be a putative Stat binding site. We did not ®nd any consensus IFN-stimulated response element (ISRE) or interferon regulatory factor element (IRF-E) in CD26 promoter. In this report, we analyse the eects of IFNs and RA on CD26 expression in human B-CLL. Our data indicate that upregulation of CD26 expression by IFNs and RA is associated with Stat1a activation, suggesting that IFNs and RA stimulate CD26 gene expression at least through its GAS motif.
Results

Increase in CD26 protein induced by IFNs and RA in freshly isolated B-CLL cells
As shown in Figure 1a , the culture of B-CLL cells in the presence of IFNs (1000 U/mL) or RA (10 75 M) led to an increase in the percentage of CD26-positive cells as well as in surface CD26 density. Using cell permeabilization to allow CD26 intracellular staining, we also found a marked increase in intracellular expression of CD26 in IFN-and RA-cultured cells when compared to control cells (Figure 1a) . In all the cases examined, IFNs and RA increased the levels of surface and intracellular CD26 protein, although the strength of the responses diered from one patient to another (data not shown). In some patients, IFN-a was the best eector whereas in other patients, all IFNs exhibited similar upregulation of CD26 (data not shown). Maximal eects of IFNs or RA were observed within 24 h at 1000 U/mL for IFNs and 0.5 ± 1610
75 M for RA. To exclude the possibility that CD26 was due to residual T cells in the malignant cell population, B-CLL cells were costained with antibodies to CD20 and CD26 and analysed by two-color direct immuno¯uorescence. Figure 1b shows one representative case in which unstimulated CD20 + B-CLL cells expressed CD26 at low levels (520%) (panel c) and IFN-b stimulation resulted in the appearance of a CD20 + CD26 + subpopulation (40%) (panel f), thus con®rming the modulation of CD26 on malignant B cells.
Through IRF-1 activation of the IFN-a gene, RA increases synthesis and secretion of IFN-a in the myeloid HL-60 and NB4 cell lines (Gianni et al., 1997; Pelicano et al., 1997) . ELISA of the culture media from unstimulated and stimulated (for up to 72 h) B-CLL cells, however, showed no release of IFN-a or IFN-g (data not shown), thus indicating that RA did not act on CD26 expression through an IFN-dependent pathway. CD26 upregulation is correlated with an increase in DPPIV activity
We investigated whether CD26 upregulation was associated with enhanced DPPIV enzymatic activity which was assessed by measuring the rate of hydrolysis of the chromogenic substrate Gly-Pro-pNA. As shown in Table 1 , Gly-Pro-pNA hydrolysis was increased after IFN-and RA-treatment. This stimulation paralleled the increase in CD26 expression previously observed under the same conditions. Moreover, prodipine, the speci®c inhibitor of DPPIV (Lambeir et al., 1996) , eliminated Gly-Pro-pNA hydrolysis whereas CD26 mAb used to phenotype B-CLL cells immunoprecipitated Gly-Pro-hydrolyzing activity in B-CLL lysates (Table 1) . Taken together, these data indicate that augmented levels of DPPIV activity in IFN-and RA-stimulated B-CLL cells were attributable to the induction of CD26.
Eects of IFNs and RA on IRF-1 and CD26 mRNA levels in B-CLL cells
We next determined whether such CD26 protein upregulation was due to an induction of CD26 gene expression. We analysed by RT±PCR the eects of IFNs or RA on the mRNA levels of CD26 in B-CLL cells, and examined in parallel the levels of IRF-1 mRNA in the B-CLL samples, since IFNs and RA are able to activate at least the IRF-1 gene in myeloid cell lines (Igarashi et al., 1994; Matikainen et al., 1996; Gianni et al., 1997; Pelicano et al., 1997 ). An accumulation of IRF-1 and CD26 transcripts by IFNs or RA was evident at 2 h ( Figure 2 , B-CLL1) and this upregulation persisted for 4 h (Figure 2 , B-CLL2). Treatment with IFNs or RA for longer periods (up to 72 h) led to sustained elevated levels of IRF-1 and CD26 mRNAs (Figure 2 , B-CLL3-6). The kinetics and strength of the responses, however, diered among IFNs, IFN-g being more eective than IFNs a and b after 24 h (Figure 2 ). These data indicate that upregulation of both IRF-1 and CD26 transcripts by IFNs or RA is a rapid and long-lasting process. IFNs and RA had little eect on the expression of IRF-2 mRNA (data not shown).
Eects of IFNs and RA on the levels of Stat1a protein and its tyrosine phosphorylation status in B-CLL cells
Western blots analyses were performed to determine whether Stat1a, which is known to be involved in IFNand RA-signaling pathways (Igarashi et al., 1994; Gianni et al., 1997; Pelicano et al., 1997) , was affected in IFN-or RA-stimulated B-CLL cells. As shown in Figure 3a , IFNs and RA enhanced levels of tyrosinephosphorylated Stat1a (p-Stat1a) and the increased tyrosine phosphorylation was already observed at 1 h of stimulation ( Figure 3a) . We also performed immunoblot analysis of nuclei of B-CLL cells treated or not with IFN-g or RA. As shown in Figure 3b , the levels of Stat1a protein appeared to be higher in the nuclei of IFN-/RA-stimulated cells than in control cells and Stat1a bands were therefore standardized to the nuclear actin constant probe. Amounts of pStat1a were markedly augmented in the nuclei of IFN-g-and RAtreated cells (Figure 3b ). Quantitative analysis indicated a twofold enrichment of p-Stat1a with RA and a fourfold enrichment with IFN-g ( Figure 3b ) which correlate the levels of Stat1a, thus indicating that Stat1a translocated to the nucleus is tyrosine-phosphorylated.
Stat1a protein levels in myeloid cells are enhanced by IFNs (Eilers et al., 1993; Pine et al., 1994; Lehtonen et al., 1997) and RA (Kolla et al., 1996; Gianni et al., 1997; Pelicano et al., 1997; Weihua et al., 1997) . We found that Stat1a protein levels in B-CLL lysates were dierently upregulated with time following IFN-or RA-treatment (Figure 3c ). Quantitation using actin expression indicated that in IFN-treated B-CLL cells, Stat1a protein levels increased at 24 h and decreased at Following 48-h incubation with or without IFNs (1000 U/mL) or RA (10 75 M), B-CLL lysates were incubated with 1 mg/mL Gly-Pro-pNA for 1 h at 378C in the absence or presence of 1 mM prodipine. In parallel, cell lysates precleared with CD26 mAb and Protein GSepharose, were incubated with 1 mg/mL Gly-Pro-pNA for 1 h at 378C. Gly-Pro-hydrolyzing activity was expressed as the percentage of the control activity. S.D. for 3 B-CLL samples (100% of unstimulated cells represent 236+5 pmol of pNA formed/30 min mg protein at 378C) IFN-g and RA activate the binding of Stat1a to the GAS motifs of CD26 and IRF-1 promoters
We examined whether the GAS motif in the promoter of CD26 could be involved in IFN-or RA-inducibility. Equal amounts of total or nuclear extracts from unstimulated or IFN-g or RA-stimulated B-CLL cells were used in gel mobility shift assays with a 32 P-labeled oligonucleotide of the GAS motif of the CD26 promoter. EMSA indicated that untreated B-CLL cells contain detectable levels of a factor able to bind to the GAS-CD26 element (Figure 4a ), and stimulation with IFN-g or RA resulted in activation of the binding of this factor to GAS-CD26 (Figure 4a ). Enhanced formation of this complex was still detectable 20 h after IFN or RA treatment as seen in two representative cases (Figure 4b , patients 1 and 2). DNA binding activity stimulated by IFN-g and RA was respectively observed in seven of nine, and ®ve of nine patients tested. However, in two patients, DNA binding activity was not increased following IFN-g or RA treatment, as shown in Figure 4b in one representative case (patient 3).
In parallel, using a 32 P-labeled oligonucleotide containing the GAS-IRF-1 binding site, we found basal DNA binding of a nuclear protein, and both IFN-g and RA increased the levels of this complex (Figure 5a ). This binding was speci®c since excess unlabeled GAS-CD26 or GAS-IRF-1 oligonucleotides competed (Figure 5b ). No major change was detected following the addition of Stat1a Ab (Figure 5b ). Stat1a Ab nevertheless inhibited the Stat1-GAS-IRF-1 complex from IFN-stimulated osteosarcoma Saos cells (Figure 5c ). With regard to GAS-CD26, excess unlabeled CD26 or IRF-1 probes also eectively competed for this binding (Figure 6a ). As with GAS-IRF-1, addition of Stat1a Ab did not result in the disappearance of the original complex (Figure 6a ). Abs directed against IRF-2, Stat3, Stat5, ISGF-3g p48 and Stat1a/Stat1b were also ineective (data not shown). We used shift-Western blot analysis to identify the protein(s) in the DNA-protein complexes of GAS-CD26 and GAS-IRF-1. Probing with Stat2 Ab did not cause the appearance of any reactive band (data not shown) whereas a band reacting with Stat1a Ab was observed in protein-GAS-IRF-1 and protein-GAS-CD26 complexes (Figure 6b ). Serine residues in Stat1a were previously shown to enhance the highanity binding of Stat1a homodimer to the GAS P-labeled GAS-CD26 probe and the protein DNA-binding was analysed by EMSA sequence of IRF-1 (Eilers et al., 1995) . We found here that Stat1a containing bands were serine-phosphorylated with the use of a phosphoserine Ab (Figure 6b ). From these data, it may be suggested that serine phosphorylation of Stat1a increases the anity of Stat1a for GAS-CD26, leading to the inability of Stat1 Abs to block formation of the protein-DNA complex.
Discussion
It has been known for several years that IFNs directly stimulate the expression of some genes, including IRF-1, through their GAS motifs (Igarashi et al., 1994) . Recently, Pelicano et al. (1997) showed that the GAS motif in the IRF-1 promoter can also mediate the induction of IRF-1 in response to RA. Our present data have provided evidence that IRF-1 gene activation in B-CLL is controlled by IFNs and RA, and most importantly that the promoter of the CD26 gene (via a GAS element at position 735 to 727) can be a direct target for IFNs and RA.
The GAS element recognizes Stat1a whose induced tyrosine phosphorylation, homodimerization and DNA binding are critical for initiation of gene expression (Shuai, 1994; Eilers et al., 1995) . Moreover, hyperphosphorylation on serine residues of Stat1 appears to be crucial for maximal transcriptional activity of the Stat1 dimer, which thus binds with high anity to GAS sites (Eilers et al., 1995; Wen et al., 1995) . Here, when B-CLL cell lysates from untreated patients were immunoprecipitated with Stat1a Ab and blotted for phosphoserine, Stat1a was found to be serine-phosphorylated and IFNs or RA did not modify its level of serine phosphorylation (data not shown). We also found Stat1a to be tyrosinephosphorylated in untreated B-CLL cells, and IFNs or RA were able to enhance tyrosine phosphorylation of Stat1a (Figure 3 ). Activated Stat1a in the nuclei of B-CLL cells displayed high-anity binding to the GAS sequence of CD26 promoter (Figure 4) . Increased Stat1a DNA-binding activity to the GAS-CD26 sequence by IFNs or RA appeared to correlate with a rapid enhancement of CD26 mRNA levels (Figure 2) . Induction of IRF-1 gene by the Stat1 signaling pathway was also observed in IFN-and RAstimulated B-CLL cells (Figures 2 and 5 ). Intracellular and surface CD26 protein levels were upregulated as a consequence of increased levels of the CD26 transcript in IFN-and RA-activated B-CLL cells (Figure 1) . Importantly, the upregulation of the CD26 protein by IFNs and RA was associated with functional DPPIV activity (Table 1) .
CD26 and IRF-1 mRNA levels remained elevated up to 48 h following IFN or RA treatment in B-CLL cells (Figure 2 ). Human Stat1 gene has been reported to be activated by IFNs (Eilers et al., 1993; Pine et al., 1994; Lehtonen et al., 1997; Matikainen et al., 1999) Figure 5 EMSA analysis of protein-GAS-IRF-1 formation in B-CLL cells treated with IFN-g or RA. B-CLL cells were stimulated with IFN-g (1000 U/mL) or RA (10 75 M) for the times indicated. Nuclear extracts were assayed for GAS-IRF-1 binding activity in the absence (a) or presence of 2 mg of Stat1a Ab or a 75-fold excess of respective unlabeled oligonucleotides containing the GAS-CD26 or GAS-IRF-1 sequences (b), and subjected to EMSA. The nuclear extract obtained from IFN-g-stimulated Saos cells was incubated under the same conditions with the 32 P-labeled GAS-IRF-1 and Stat1a Ab (2 mg) and served as control (c) Figure 6 Stat1a protein is the nuclear factor binding to GAS-CD26 and GAS-IRF-1 probes. (a) Nuclear extracts obtained from B-CLL cells cultured in the absence (none) or presence of IFN-g (1000 U/mL) or RA (10 75 M) for 20 h, were tested for GAS-CD26 binding activity in the absence or presence of 2 mg of Stat1a Ab or excess of unlabeled oligonucleotides containing the GAS-CD26 (500-fold) or GAS-IRF-1 (75-fold) sequences, and subjected to EMSA. (b) GAS-CD26 and GAS-IRF-1 oligonucleotides and nuclear extracts from B-CLL cells treated for 20 h with or without IFN-g (1000 U/mL). After EMSA, the protein of the protein-DNA complexes was transferred by capillarity to a nitrocellulose membrane and revealed by Western blot analysis using Stat1a (rabbit polyclonal IgG) or phosphoserine (mIgG1) Abs and RA (Kolla et al., 1996; Gianni et al., 1997; Matikainen et al., 1998) . At present, there is no information on the Stat1 promoter regulatory elements that would account for IFN-induced expression of Stat1. The murine promoter of Stat1 directly responds to RA treatment through a direct repeat motif that serves as an RA responsive element (RARE) (Weihua et al., 1997) . Our data showed that Stat1a protein was constitutively expressed in unstimulated B-CLL cells (Figure 3) . With IFNs, the Stat1a protein level increased at 24 h and diminished at 72 h, whereas RA started to increase Stat1a protein at 72 h ( Figure  3c ). Such augmentations may explain the long-lasting activation of CD26 gene by IFNs or RA (Figures 2  and 4) .
IFN types I and II activate IFN regulatory factor 1 (IFR-1), IRF-3 and ISGF3 complex (consisting of Stat1a, Stat2 and p48), which may bind IFNstimulated response element (ISRE) sequences overlapping with the interferon regulatory factor element (IRF-E) (Harada et al., 1998; Pitha et al., 1998; FloydSmith et al., 1999) . However, no ISRE nor IRF-E sequences were found in CD26 promoter, thus excluding the participation of these factors in CD26 gene activation. The promoter of human CD26 gene contains other putative binding sites for Sp1, AP-1/2, ETF, HNF-1 and NF-kB (Abbott et al., 1994; BoÈ hm et al., 1995) . It is therefore possible that additional signaling pathways interfere with Stat1a in activating the CD26 gene.
B-CLL is characterized by an accumulation in the blood of a large number of nonproliferative and long-lived malignant B cells (Osorio et al., 1998) . Clinical data showed some bene®cial eect of IFN-a as maintenance therapy in the early phases of B-CLL (Foon et al., 1985; McSweeney et al., 1993) . It has been suggested that endogenously produced cytokines could regulate B-CLL growth (Osorio et al., 1998) . Moreover, cell-bone marrow stroma interactions could prevent apoptosis of malignant B cells (Lagneaux et al., 1998) . Recent data obtained by delaFuente et al. (1999) demonstrated that adhesion of B-CLL cells to ®bronectin via a4b1 integrin prevented cell apoptosis. We do not yet know the biological signi®cance of the CD26 upregulation by IFNs or RA that we observe in B-CLL. Several functions have been postulated for CD26. Based on its enzymatic properties, CD26 could regulate cell growth through the activation/inactivation of crucial factors (Fleisher, 1994; De Meester et al., 1999) . In T cells, CD26 is involved in CD3/T cell receptor (TcR)-mediated signal transduction leading to cell activation and IL-2 secretion (Fleisher, 1994; De Meester et al., 1999) . Moreover, CD26 has the ability to bind adenosine deaminase binding protein and interacts with the extracellular matrix via ®bronectin and collagen (Fleisher, 1994; De Meester et al., 1999) . Con¯icting data have recently been reported with regard to the potential role of CD26 in apoptosis. Transfection of CD26 cDNA into HIV-infected Jurkat cells protected them from apoptosis (Morimoto et al., 1994) whereas CD26-speci®c antibodies induced apoptosis of some hepatocarcinoma cell lines (Gaetaniello et al., 1998) . Whether upregulation of CD26 confers on B-CLL cells a selective advantage or disadvantage remains to be determined.
During the process of this manuscript, another group reported loss of CD26 expression during malignant transformation of melanocytes to melanoma (Wesley et al., 1999) . Conversely, the inducible gene transduction of CD26 into melanoma cells reversed the malignant phenotype of the cells toward normal melanocytes (Wesley et al., 1999) thus suggesting that CD26 downregulation represents an important event in the pathogenesis of melanoma cells. In light of the important physiological and pathophysiological contexts of CD26 (Iwata and Morimoto, 1999) , understanding how the CD26 gene is controlled appears crucial. Our study shows for the ®rst time that IFNs and RA upregulate the expression of CD26 gene. Further studies are required to understand the biological signi®cance of the eects of IFNs and RA on CD26 expression in B-CLL malignancy.
Materials and methods
Materials
Rhodamine (RD)-conjugated CD26 (Ta1, mIgG1) mAb, uorescein isothiocyanate (FITC)-conjugated CD20 (B1, mIgG2a), RD-conjugated mIgG1 and FITC-conjugated mIgG2a were from Coulter-Immunotech (Coultronics, Margency, France). Stat1a (C-24, rabbit polyclonal IgG), tyrosine-phosphorylated Stat1 (p-Stat1, goat polyclonal IgG), Stat1a/Stat1b (p84/p91, C-136, mIgG1), Stat2 (C-20, rabbit polyclonal IgG), Stat3 (H-190, rabbit polyclonal IgG), Stat-5 (G-2, mIgG1), ISGF-3g p48 (C-20, rabbit polyclonal IgG) and IRF-2 (C-19, rabbit polyclonal IgG) Abs were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Ficoll-Hypaque was from Pharmacia (Uppsala, Sweden). Gly-Pro-p-nitroanilide (pNA) and phosphoserine mAb (PSR-45, mIgG1) were from Sigma Chemical Co. (Saint Louis, MO, USA). Human recombinant interferongamma (rIFN-g) (2610 7 U/mg) was provided by RousselUclaf (Romainville, France). Human rIFN-a2a (2610 8 U/ mg) and all trans retinoic acid (RA) were provided by Homan-La Roche (Basel, Switzerland). Human rIFN-b (2610 8 U/mg) was provided by Ares-Serono (Geneva, Switzerland). Pro-Pro-diphenyl phosphonate ester (prodipine) was synthesized and characterized previously (Lambeir et al., 1996) . Kits for enzyme-linked immunoadsorbent assay (ELISA) of IFN-a and IFN-b were from CoulterImmunotech (Coultronics, Margency, France). Puri®ed synthetic oligonucleotides were provided by Oligo express (Paris, France) covering the GAS elements of the CD26 gene (BoÈ hm et al., 1995) 5'-GCGCTCCTTCTC-TGAACGCTCAC-3', and of the IRF-1 gene (Pine et al., 1994) 5'-AGCTTCAGCCTGATTTCCCCGAAATGACG-GA-3'.
Cells
Mononuclear cells from 18 untreated patients with B cell chronic lymphocytic leukemia (B-CLL) were isolated by Ficoll-Hypaque density gradient centrifugation, pelleted and used immediately. B-CLL diagnosis was established according to the international CLL workshop criteria including peripheral blood lymphocyte morphology and coexpression of CD5, CD20 and CD23 antigens. The mononuclear cell population contained 510% CD3 + and CD14 + cells and 490% CD20 + CD23 + cells. B-CLL cells were cultured in RPMI 1640 medium containing 2 mM L-glutamine, 10 mg/mL gentamycin and 10% fetal calf serum (FCS, Gibco) at a seeding density of 1 ± 2610 6 cells/mL.
Flow cytometry analysis
Intact cells were immunostained as previously described (Bauvois et al., 1999) . Cells were permeabilized by ®xing in 4% formaldehyde containing 50% EtOH for 10 min at room temperature. After washing with PBS, the cells were incubated in PBS containing 0.2% Tween for 5 min at room temperature. Cells were washed and further stained with the mAb in PBS containing 0.025% Tween. Analysis was performed in a FACS¯ow cytometer analyser (BectonDickinson, Mountain View, CA, USA); 10 000 events were recorded and analysed using Lysys software (Becton Dickinson). Fluorescence data were expressed in relativē uorescence intensity (%), and antigen relative density per cell (obtained by subtracting the peak channel number of the negative control from the peak channel number of the corresponding experimental sample).
DPPIV activity assay
DPPIV activity in cell lysates was measured spectrophotometrically by hydrolysis of Gly-Pro-pNA and formation of pNA, as previously described (Bauvois et al., 1999) . Cells were lysed in protease buer and 1% (w/v) n-octyl-b-Dglucoside. Whole cell lysates (10 ± 50 mg protein) in 50 ml were incubated for 18 h at 48C with CD26 mAb (10 mg) or an equivalent amount of control isotype mIgG1, and the immunoprecipitates were obtained by adding Protein GSepharose (Pharmacia, 20 ml) for 3 h at 48C. After centrifugation, the immunoprecipitates bound to Protein GSepharose beads were tested for DPPIV activity by incubation with Gly-Pro-pNA (1 mg/mL).
Western blot analysis
Total homogenates were obtained by solubilizing the cells at 48C in 50 mM HEPES pH 7.6 containing 150 mM NaCl, 1 mM EDTA, 1.5 mM MgCl 2 , 5 mg/mL aprotinin, 5 mg/mL leupeptin, 100 mM NaF, 1 mM orthovanadate and 1 mM phenylmethylsulfonyl¯uoride and 1% (w/v) n-octyl-b-Dglucoside. After lysis, the total extracts were centrifuged for 20 min at 10 000 r.p.m. at 48C. Aliquots of the supernatants (20 ± 40 mg protein) were mixed with 26SDS sample buer in the presence of 1% b-mercaptoethanol and denatured at 1008C for 5 min. Equivalent amounts of protein were separated on 7.5% polyacrylamide-SDS gels and the protein bands were transferred to nitrocellulose ®lters (BA 83, 0.2 mm, Schleicher and Schuell, NH, USA). Membranes were hybridized and processed by the established method using chemiluminescence technique developed by ECL (Amersham, Buckinghamshire, England). Immunoreactive protein bands were detected by autoradiography onto Hyper®lms (Amersham). Quantitation was performed using the Image 1.44b11 software (MacIntosh Inc.).
RNA extraction and RT±PCR
RNA preparation, subsequent cDNA synthesis and amplification via PCR were conducted for CD26 and b2-microglobulin transcripts as previously described (Bauvois et al., 1999) and for IRF-1 transcript as described in (Hochhaus et al., 1997) . Image 1.44b11 software was used for the analysis.
Nuclear extract preparation and electrophoretic mobility shift assay Nuclear extracts from B-CLL cells unstimulated or stimulated with IFNs or RA were prepared as previously described (Djavaheri-Mergny et al., 1999) . Nuclear extracts were kept frozen in aliquots at 7808C until use. GAS-CD26 and GAS-IRF-1 oligonucleotides were 32 P-labeled with [g-32 P] ATP, using T 4 polynucleotide kinase. Nuclear (5 ± 10 mg) or whole extracts (40 mg) were incubated with the radiolabeled DNA probe (0.1 pmol, 20 000 ± 40 000 c.p.m.) at 48C for 30 min. Complexes were separated from the free probe in 6% (w/v) nondenaturing polyacrylamide gels containing 45 mM Tris pH 8.3, 45 mM borate and 0.1 mM EDTA. Gels were dried and exposed to a PhosphorImager screen (Molecular Dynamics, Sunnyvale, CA, USA). For competition and characterization experiments, extracts were preincubated with binding buer and unlabeled oligonucleotides or appropriate Abs for 30 min at 48C before adding the radiolabeled probe.
Shift-Western blotting
Nuclear extracts (40 mg) were prepared and assayed for GAS-CD26 or GAS-IRF-1 DNA-binding activity as described above. After polyacrylamide gel electrophoresis, the gel was exposed for 30 min at 48C to PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA), then transferred by capillarity to a nitrocellulose membrane. The membrane was ®rst exposed to Stat1a Ab (rabbit polyclonal IgG) as described above for Western blot analysis. The complete removal of primary and secondary Abs from the membrane was performed by submerging the membrane in 100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl pH 6.7 and incubating at 508C for 30 min, followed by extensive washing in TBS-T at room temperature, and then controlled for lack of immunodetection with Stat2 Ab (rabbit polyclonal IgG). The membrane was thus reprobed with phosphoserine Ab (mIgG1).
